NASDAQ: CRDL) (TSX: CRDL) " src="https://www.globalnewslines.com/uploads/2026/04/1776052997.jpg" alt="$30 Billion Per Year US Heart Failure Market Presents Huge Opportunity for Promising Drugs Advancing with Positive Trial Results for Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) " width="225" height="218">

• Late-Stage Life Sciences Company Focused on Advancing Development of Anti-Inflammatory and Anti-Fibrotic Therapies for Heart Disease.

• CardiolRx™, Modulates Inflammasome Activation, an Intracellular Process driving Inflammation and Fibrosis in Pericarditis, Myocarditis and Heart Failure.

• Also Developing CRD-38, Drug Formulation for Inflammatory Heart Disease, Including Heart Failure.

• Heart Failure is a Leading Cause of Death and Hospitalization with Associated Healthcare Costs in the United States Exceeding US$30 Billion Per Year.

• Initiated Pivotal Phase III MAVERIC Trial of CardiolRx™ in Recurrent Pericarditis and Surpassed 50% Patient Enrollment, with Full Enrollment Expected in Q2 2026.

• Positive Phase II ARCHER Data Showing CardiolRx™ Significantly Reduced Left Ventricular Mass in Patients with Acute Myocarditis.

• Advancing CRD-38 Program, to Support an Investigational New Drug ("IND") Application and the Initiation of Phase I Clinical Development.

• Received U.S. Patent Allowance Broadly Protecting CardiolRx™ and CRD-38 for Treatment or Prevention of Cardiac Conditions Through Late 2040.

• Strengthened Board of Directors with Election of Dr. Timothy Garnett, Former Chief Medical Officer of Eli Lilly and Company.

• Raised Aggregate Gross Proceeds of $31 Million Providing a Cash Into Q4 2027.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The CRDL lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.

The MAVERIC Program is evaluating CRDL CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study and the ongoing pivotal Phase III MAVERIC trial. The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.

The ARCHER Program is also studying CRDL CardiolRx™, specifically in acute myocarditis-an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study, which evaluated the safety, tolerability, and efficacy of CRDL CardiolRx™ in this patient population.

CRDL is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure-a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.

Year-End 2025 Update on Operations

On April 1st CRDL announced its year-end 2025 update on operations following the filing of its audited Financial Statements and Management's Discussion and Analysis for the year ended December 31, 2025.

"2025 was a pivotal year of clinical execution and strategic advancement for CRDL. We initiated our Phase III MAVERIC trial in recurrent pericarditis, reported positive Phase II ARCHER data demonstrating that CardiolRx™ improves the underlying biology of inflammatory heart disease and reduces inflammation-driven structural damage, and strengthened our balance sheet to support key value-inflection milestones," said David Elsley, President and Chief Executive Officer of CRDL.

"We are now fully funded through completion of the MAVERIC trial, which is designed to support a New Drug Application submission for CardiolRx™ in the prevention of recurrent pericarditis-an expanding market with a significant unmet need for a safe, accessible, non-immunosuppressive oral therapy. In parallel, the positive ARCHER results-our second successful Phase II study in inflammatory heart disease-along with continued expansion of our patent portfolio in the United States and advancement of CRD-38 toward IND submission, further strengthen our product pipeline.”

Other Key Highlights

In November 2025, CRDL received a U.S. patent allowance broadly protecting its heart drugs, including CardiolRx™ and CRD-38, for use in the treatment or prevention of an extensive range of cardiac conditions, including heart failure, myocarditis, acute pericarditis, inflammatory cardiomyopathy, cardiac toxicity from anti-cancer therapies, and atherosclerosis, to October 2040. The patent allowance covers new areas of heart disease, including those identified for potential research expansion based on the ARCHER findings, adding extensive intellectual property protection to the Company's product portfolio.

In May 2025, Dr. Timothy J. Garnett was elected to the Board of Directors. Dr. Garnett served as Chief Medical Officer of Eli Lilly and Company from 2008 to 2021, where he led the development and global commercial launch of multiple therapeutics across a 20-year tenure. His regulatory and commercialization experience strengthens the Board as CRDL approaches potential registrational milestones.

In October 2025, CRDL completed a private placement for total proceeds of approximately $16 million. Subsequent to year-end, in January 2026, CRDL closed a bought deal financing with full exercise of the over-allotment option for gross proceeds of $14.85 million. The combined financings provide a cash runway into Q4 2027.

CRDL strategic priorities include the following:

Complete full patient enrollment in the Phase III MAVERIC trial to enable timely progression toward topline data reporting and a potential NDA submission.

Initiate clinical development of CRDL CRD-38 to establish a second major value-driver for the treatment of heart disease.

Collaborate with KOLs in inflammatory heart disease to evaluate additional high-value rare disease programs, leveraging the ARCHER results.

Advance discussions and negotiations with prospective strategic partners to provide global market access and maximize the commercial potential of the CRDL drug candidates.

Continue to broaden awareness of CRDL groundbreaking research through presentations at major cardiology conferences and publications in peer-reviewed journals.

For more information on CRDL visit : www.cardiolrx.com

Email: info@cardiolrx.com

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website

Media Contact
Company Name: Cardiol Therapeutics Inc. (NASDAQ: CRDL)
Contact Person: David Elsley, CEO
Email: Send Email
Phone: (289) 910-0850
Address:2265 Upper Middle Road East Suite 602
City: Oakville
State: ON L6H 0G5
Country: Canada
Website: https://www.cardiolrx.com/